ZYUS LIFE SCIENCES

WCB-SK Dosage Form

Section 1 - Patient Information							
Patient's First Name		Patient's Last Name			WCB Claim Number		
Patient Address							
City	City Province		Postal Code		ll Code		
Section 2 - Product Selection (Ratio of Active Ingredients)							
Low TH	C : High CBD		Balanc	ed (THC:CB	(D)		
	Zylem™ 1:20 Oil (50 mL) Total THC 1 mg/g Total CBD 20mg/g Total THC per activation 0.9mg/mL Total CBD per activation 18mg/mL			Zylem™ 10:10 Oil (50 mL) Total THC 10 mg/g Total CBD 10mg/g Total THC per activation 9mg/mL Total CBD per activation 9mg/mL			
	mg)	cal THC per unit 1.0mg Total CBD per			Zylem™ 5:5 Softgels (60 cc x 210 mg) Total THC per unit 5.0mg Total CBD per unit 5.0mg		
Section 3 - Dosage (Required by WCB-SK for authorized formulations)							
Zylem TM	4 1:20 Oil (50 mL)		Zylem	TM 10:10 Oil	(50 mL)		
	mLs, times per da	y.		mLs,	times p	er day.	
	max mLs per day.			max mLs per day.			
max bottles per month.			max bottles per month.				
Zylem™ 1:20 Softgels (60 cc x 210 mg)			Zylem™ 5:5 Softgels (60 cc x 210 mg)				
	softgel capsules, ti	mes per day.		softgel capsu	ıles,	times per day.	
max softgel capsules per day.			max softgel capsules per day.				
max bottles per month.			max bottles per month.				
Section 4 - Healthcare Practitioner Information							
Healthcare Practitioner's First Name				Healthcare Practitioner's Last Name			
Signature			Date (mm/dd/yyyy)				
FAX Completed Form to WCB-SK							
WCB-SK FAX Number 1.888.844.7773							

This form must be completed by the patient's authorizing healthcare practitioner and the information contained herein is intended to be used by the Workers' Compensation Board of Saskatchewan ("WCB-SK") solely for the purpose of WCB-SK determining benefit coverage for the patient named herein. Notwithstanding any information provided by the patient's healthcare practitioner herein, this document does not serve as, replace, amend or in any way limit the medical authorization issued by the patient's healthcare practitioner ("Patient's Medical Authorization") under the *Cannabis Act* (Canada) and the regulations thereto and ZYUS Life Sciences Inc. ("ZYUS") is governed by and shall rely upon the Patient's Medical Authorization respecting sale and delivery of products to the patient. If there is a conflict or inconsistency between the information set out herein and the information set out in the Patient's Medical Authorization, ZYUS shall rely upon and be governed by the Patient's Medical Authorization.